OXFORD NANOPORE TECHNOLOGIES, INC.

Oxford Nanopore Technologies Inc. specializes in the design, manufacturing, and support of long-read genomic sequencing systems and associated reagents, primarily serving federal research and diagnostic laboratories. Their core capabilities center on Oxford Nanopore’s nanopore-based sequencing platforms, including PromethION and GridION instruments, flow cells, and reagent kits for direct RNA, cDNA, and DNA sequencing. The contractor provides end-to-end technical support, including instrument maintenance, licensing, and warranty services, ensuring continuous operation of high-throughput sequencing systems in sensitive research environments. Their technical expertise spans molecular biology sample preparation, real-time sequencing data generation, and bioinformatics integration, with a strong focus on applications in genomics, infectious disease research, and functional genomics. The company maintains a dominant relationship with the Department of Health and Human Services, delivering sequencing instruments, reagents, and maintenance services to NIH institutes such as NHGRI and NHLBI for projects involving ALS pathology, HIV reservoirs, and islet cell biology. They also support the Department of Agriculture in biotechnological research and engage with the Department of Defense on advanced genomic analysis initiatives. Their work is consistently aligned with mission-critical, non-diagnostic research requiring high-fidelity, real-time nucleic acid sequencing. Industry focus is firmly rooted in analytical laboratory instrument manufacturing and biotechnology R&D, with secondary activity in in-vitro diagnostic substance manufacturing and precision equipment repair. The contractor positions itself as a niche provider of cutting-edge sequencing infrastructure for government-funded life sciences research, distinguishing itself through proprietary nanopore technology and direct RNA sequencing capabilities not widely replicated in the market. Oxford Nanopore Technologies Inc. is a limited liability entity based in New York, NY, with no federal certifications on record. Their market presence is defined by deep technical engagement with federal research agencies rather than broad commercial distribution, establishing them as a specialized supplier to the U.S. government’s genomic research ecosystem.